Federal Judge Beryl A. Howell will rule in the coming months on a case filed by the Pharmaceutical Research and Manufacturers of America against the Federal Trade Commission over last year's rule exposing many more drug patent transfers to antitrust review. The central issue in the case will likely be the claim of PhRMA that the policy is discriminatory for isolating drug license deals for additional disclosure burdens, McDermott Will & Emery's Jon Dubrow said.

Related Summaries